HGI-001 is under clinical development by Shenzhen Hemogen Gene Biotechnology and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HGI-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HGI-001 overview

HGI-001 is under development for the treatment of beta-thalassemia. The therapy comprises of autologous hematopoietic stem cells genetically modified with lentiviral vector LentiHBBT87Q encoding the human beta-globin gene, administered intravenous.

Shenzhen Hemogen Gene Biotechnology overview

Shenzhen Hemogen Gene Biotechnology (Hemogen) is focused on the research, development, and application of hematopoietic stem cell gene therapy and genetic engineering technologies for the hemoglobin diseases.

For a complete picture of HGI-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.